The Company was established in 1995 with the name of Fujisawa Hong Kong, Ltd., a wholly-owned subsidiary of Fujisawa Taiwan Co., Ltd. To cope with the business development in China, the Company was renamed as Fujisawa Pharmaceuticals (China) Co., Ltd. in 2003.

On 1st April, 2005, Astellas Pharma Inc. was established through a merger of Yamanouchi Pharmaceutical Company Limited and Fujisawa Pharmaceutical Company Limited. This merger created the second-biggest Japanese pharmaceutical company by sales and marked the first major consolidation in the Japanese pharmaceutical industry.

Being the wholly-owned subsidiary of Astellas Pharma Inc., Astellas Pharma Hong Kong Company Limited was renamed on 1st April, 2007 from Fujisawa Pharmaceuticals (China) Co., Ltd. as a result of the inauguration of Astellas Pharma Inc. and the following reorganization of Astellas Group companies.

Astellas Pharma Hong Kong Company Limited plays an important role in the Hong Kong Pharmaceutical Industry. Being a full member of The Hong Kong Association of the Pharmaceutical Industry, we focus on sales and marketing of our products in both Hong Kong and Macau markets for the treatment of five major therapeutic areas – Immunology, Anti-infective, Urology, Oncology and Metabolic.